74 related articles for article (PubMed ID: 9848456)
1. Comparative in-vitro activity of levofloxacin against Chlamydia spp.
Donati M; Rumpianesi F; Marchetti F; Sambri V; Cevenini R
J Antimicrob Chemother; 1998 Nov; 42(5):670-1. PubMed ID: 9848456
[No Abstract] [Full Text] [Related]
2. In vitro and in vivo activities of sitafloxacin against Chlamydia spp.
Miyashita N; Niki Y; Matsushima T
Antimicrob Agents Chemother; 2001 Nov; 45(11):3270-2. PubMed ID: 11600398
[TBL] [Abstract][Full Text] [Related]
3. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
Hammerschlag MR; Roblin PM
J Antimicrob Chemother; 2004 Jul; 54(1):281-2. PubMed ID: 15190026
[No Abstract] [Full Text] [Related]
4. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of Chlamydia pecorum to macrolides, tetracyclines, quinolones and beta-lactam.
Pudjiatmoko ; Fukushi H; Ochiai Y; Yamaguchi T; Hirai K
Microbiol Immunol; 1998; 42(1):61-3. PubMed ID: 9525782
[TBL] [Abstract][Full Text] [Related]
6. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.
Bebear CM; Renaudin H; Bryskier A; Bebear C
Antimicrob Agents Chemother; 2000 Jul; 44(7):1980-2. PubMed ID: 10858366
[TBL] [Abstract][Full Text] [Related]
7. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Hammerschlag MR; Roblin PM
Antimicrob Agents Chemother; 2000 May; 44(5):1409. PubMed ID: 10819727
[No Abstract] [Full Text] [Related]
8. [Evaluation of in vitro activity of ofloxacin against 73 strains of Chlamydia trachomatis isolated from gynecologic infections].
Catalan F; Milovanovic A; Prouteau C; Soulignac M
Pathol Biol (Paris); 1998 Feb; 46(2):144-6. PubMed ID: 9769927
[TBL] [Abstract][Full Text] [Related]
9. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae.
Fenelon LE; Mumtaz G; Ridgway GL
J Antimicrob Chemother; 1990 Dec; 26(6):763-7. PubMed ID: 2081718
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of levofloxacin and FK-037 against aerobic isolates from spontaneous bacterial peritonitis.
Cormican MG; Runyon BA; Jones RN
J Chemother; 1995 Jun; 7(3):197-200. PubMed ID: 7562013
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.
Kohlhoff SA; Roblin PM; Reznik T; Hawser S; Islam K; Hammerschlag MR
Antimicrob Agents Chemother; 2004 May; 48(5):1885-6. PubMed ID: 15105151
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1996 Aug; 38(2):259-63. PubMed ID: 8877540
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.
Smith RP; Baltch AL; Ritz WJ; Carpenter AN; Halse TA; Bopp LH
Antimicrob Agents Chemother; 2004 Jun; 48(6):2081-4. PubMed ID: 15155203
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains.
Miyashita N; Matsumoto A; Matsushima T
Microbiol Immunol; 2000; 44(4):267-9. PubMed ID: 10832970
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae.
Dhople AM; Ibanez MA
Antimicrob Agents Chemother; 1995 Sep; 39(9):2116-9. PubMed ID: 8540726
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
Ridgway GL; Salman H; Robbins MJ; Dencer C; Felmingham D
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():31-4. PubMed ID: 9484871
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales.
Johnson AP; Speller DC; Warner M; Domingue G
J Antimicrob Chemother; 1996 Nov; 38(5):907-8. PubMed ID: 8961064
[No Abstract] [Full Text] [Related]
18. [Comparative effectiveness of the strategies of etiotropic therapy of generalized chlamydia infections in young patients].
Pozniak AL; Lobzin IuV; Babkin PA
Urologiia; 2000; (5):23-6. PubMed ID: 11392219
[No Abstract] [Full Text] [Related]
19. In vitro antibacterial activity of levofloxacin.
Zhang YY; Wang F; Zhang JD; Zhu DM; Zhou L
Drugs; 1995; 49 Suppl 2():274-5. PubMed ID: 8549330
[No Abstract] [Full Text] [Related]
20. [Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
Iakovlev VP; Svetukhin AM; Blatun LA; Ukhin SA
Antibiot Khimioter; 2004; 49(8-9):57-65. PubMed ID: 15727148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
